These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 17690567)

  • 1. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
    AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC; Kim HJ; Do JH; Park SM
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
    Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
    J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation.
    McMillan JS; Bowden DS; Angus PW; McCaughan GW; Locarnini SA
    Hepatology; 1996 Dec; 24(6):1371-8. PubMed ID: 8938164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
    J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
    Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
    J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection.
    Bozdayi G; Türkyilmaz AR; Idilman R; Karatayli E; Rota S; Yurdaydin C; Bozdayi AM
    J Med Virol; 2005 Aug; 76(4):476-81. PubMed ID: 15977237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels.
    Cabrerizo M; Bartolomé J; Iñigo ER; López-Alcorocho JM; Cotonat T; Carreño V
    J Med Virol; 1998 Dec; 56(4):294-9. PubMed ID: 9829632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis.
    Liu CJ; Kao JH; Lai MY; Chen PJ; Chen DS
    J Med Virol; 2004 Apr; 72(4):545-50. PubMed ID: 14981756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection.
    Dervisevic S; Pillay D
    J HIV Ther; 2003 Nov; 8(4):89-95. PubMed ID: 14671506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.